Share this

Moderna Global Fellowship Program open to applications in Scotland

Moderna Global Fellowship Program open to applications in Scotland

30th January 2024

Biotechnology company Moderna has announced the launch of its Global Fellowship Program with a commitment to fund at least one research fellow in Scotland over the next four years

The fellowship program aims to support novel research in the field of mRNA Science across a wide range of disciplines and diseases specialties. Along with salary and research costs, the initiative will provide expert mentorship, and experiential learning while boosting industry collaboration across research, development, and innovation (RDI).

In December 2022 the UK Government signed a 10-year strategic partnership with Moderna signalling a long-term commitment to the UK.

Professor Dame Anna Dominiczak, Chief Scientist (Health) at Scottish Government commented: “mRNA has the potential to be a transformative breakthrough technology in a number of disease areas, including cancer, respiratory illnesses, and heart disease.

“The Moderna Fellowship Program is therefore very exciting and will enable us to showcase Scotland’s world-leading knowledge and talent, as well as supporting researchers on the next stage of their careers.

“I strongly encourage applications, and we have made additional support available to those interested in this opportunity as part of our continued commitment to encouraging and supporting our RDI community across Scotland.”

Applications from Scotland are to be submitted by the end of February 2024 via the Moderna Fellowship online portal.

To support applicants and ensure the highest quality applications are submitted from Scotland, a small support team has been established comprising NHS, academic, and industry colleagues.

Interested applicants can utilise the expertise of this group as part of a national internal review before application via the Fellowship portal.

For review, contact Dr Ewan A Dougall, NRS Commercial Manager ( by 12 February.

Further information

Go back to News